This is a basic profile of an NZX50 listed company. It is not investment advice. We recommend you contact a qualified adviser if you need more information.
Pacific Edge
Directory
| NZX code: | PEB |
| Short name: | Pacific Edge |
| Legal name: | Pacific Edge Limited |
| Industry sector: | Cancer Research |
| NZX50 rank: | 48 of 50 |
| Head office address: | Level 10, Otago House, Cnr Moray Place and Princes Street, Dunedin |
| Chairman: | Chris Gallaher |
| Chief executive: | Dr. Peter Meintjes |
| Financial year ended: | March |
| Locations: | New Zealand |
| Auditor: | Pwc |
| Bankers: | BNZ, ANZ, Heartland Bank, (Dunedin) |
Pacific Edge
Select chart tabs
Financial statement history
A. Recent trading and performance summary:
| Total revenue |
NPAT | Earnings per share |
|
| fye March | mln | mln | cents |
| 2018 | $3.40 | ($19.7) | (4.5) |
| 2019 | $3.82 | ($17.9) | (3.6) |
| 2020 | $4.37 | ($19.0) | (3.2) |
| 2021 | $7.70 | ($14.2) | (2.0) |
| 2022 | $11.4 | ($19.8) | (2.6) |
| 2023 | $26.1 | ($27.0) | (0.03) |
B. Recent financial position summary:
| Total assets |
Total Liabilities |
Equity ratio |
|
| fye March | mln | mln | % |
| 2018 | $19.7 | $3.0 | 84.8 |
| 2019 | $16.6 | $2.7 | 83.7 |
| 2020 | $19.3 | $4.8 | 75.1 |
| 2021 | $31.2 | $6.1 | 80.4 |
| 2022 | $115.3 | $6.9 | 94.0 |
| 2023 | $90.9 | $8.2 | 91.0 |
C. Recent cash flows and positions:
| Cash inflows |
Cash outflows |
Cash and equiv. at year end |
|
| fye March | mln | mln | mln |
| 2018 | $20.1 | $21.4 | $5.24 |
| 2019 | $17.1 | $17.5 | $4.85 |
| 2020 | $17.6 | $20.6 | $1.76 |
| 2021 | $22.2 | $19.9 | $4.13 |
| 2022 | $100.7 | $69.7 | $35.40 |
| 2023 | ($1.3) | ($5.7) | $33.23 |
D. Recent key ratio analysis:
| Earnings per share |
Price:Earnings ratio |
NTA/share | Dividend yield |
|
| fye March | cents | annual avg | dollars | annual avg % |
| 2018 | (4.5) | -8.0 | 0.035 | N/A |
| 2019 | (3.6) | -7.8 | 0.027 | N/A |
| 2020 | (3.2) | -3.4 | 0.021 | N/A |
| 2021 | (2.0) | -50.5 | 0.035 | N/A |
| 2022 | (2.6) | -36.9 | 0.133 | N/A |
| 2023 | (0.03) | 0.0 | 0.101 | N/A |
Description of trading activities
Pacific Edge is a Global company aiming to pioneer in the space of cancer diagnostics, specifically both bladder cancer diagnostics and development. Pacific Edge currently aims to specialise for patients who present ‘Hematuria’ or ‘surveillance of recurrent disease’.
Chairman profile
Chris Gallaher joined the board of Pacific Edge in 2016, and was appointed as Chairman in August of 2016. Gallaher has major experience in leading companies with CEO, and CFO roles in companies such as Arthur Young, Chartered Accountants, and Fulton Hogan. Gallager graduated from Otago University with a Bachelor of Commerce, he is also a chartered accountant.
CEO profile
As of January, 2022, Dr. Peter Meintjes commenced as the Chief executive officer of Pacific Edge. Dr. Meintjes leads the way with a wealth of experience, having spent time in the US market of molecular diagnostics. Dr. Meintjes studied at the University of Auckland gaining a Bachelor of Science, majoring in Biology. He also gained a Masters of Science degree, in Phylogenetics, and a PhD in Biological sciences, Experimental Evolution.
Links:
| Company website: | https://www.pacificedgedx.com/ |
| Investor information: | https://www.pacificedgedx.com/investors/investor-center/ |
| NZX listing: | https://www.nzx.com/companies/PEB |
| Annual reports: | https://www.pacificedgedx.com/investors/investor-center/ |